


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A compound having the formula (1)



in which:

- (a) represents a single bond or a double bond;
- W represents a CH, CH<sub>2</sub>, CHCH<sub>3</sub>, CCH<sub>3</sub> or C(CH<sub>3</sub>)<sub>2</sub> group, a C(CH<sub>2</sub>)<sub>2</sub> group (i.e. a carbon atom bearing two methylene groups linked together so as to form a spiro-cyclopropane unit) or a C(CH<sub>2</sub>)<sub>3</sub> group (i.e. a carbon atom bearing two methylene groups linked to another methylene group so as to form a spiro-cyclobutane unit) with the proviso, however, that when (a) is a double bond, then W exclusively represents a CH or CCH<sub>3</sub> group, and that when (a) is a single bond, then W exclusively represents a CH<sub>2</sub>, CHCH<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>2</sub>)<sub>2</sub> or C(CH<sub>2</sub>)<sub>3</sub> group;
- X is a carbon atom bearing a hydrogen atom (CH) or a nitrogen atom; and
- Y is a hydrogen atom or a fluorine atom;

or an addition salt or hydrate thereof with a pharmaceutically acceptable inorganic acid or organic acid or a tautomeric form, pure enantiomer or mixture of racemic or nonracemic enantiomers thereof.

2. (Currently Amended) A compound as claimed in claim 1, which is:

[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;

[2-(benzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;

[2-(2-methylbenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;

[2-(2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;

[2-(2-spirocyclopropyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine; or

[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-[3-(2-fluorocyclopenten-1-yl)benzyl]amine; ~~or~~

~~[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(5-cyclopenten-1-ylpyridine-3-yl)methyl)amine;~~

or an addition salt or hydrate of said addition salt with a pharmaceutically acceptable inorganic acid or organic acid or an isomer or tautomer thereof.

Claims 3-4 (Cancelled)


5. (Previously Presented) A pharmaceutical composition comprising, as active ingredient, at least one compound as claimed in claim 1 and an inert pharmaceutical carrier or other pharmaceutically acceptable vehicle.

6. (Previously Presented) A method for the treatment of schizophrenia comprising administering to an animal in need of such treatment an effective anti-psychotic amount of a composition as claimed in claim 5.

7. (Previously Presented) A pharmaceutical composition comprising, as active ingredient, at least one compound as claimed in claim 2 and an inert pharmaceutical carrier or other pharmaceutically acceptable vehicle.

8. (Previously Presented) A method for the treatment of schizophrenia comprising administering to an animal in need of such treatment an effective anti-psychotic amount of a composition as claimed in claim 7.

9. (Previously Presented) A process for the preparation of a compound having the formula (1) as claimed in claim 1, said process comprising reacting a compound having the formula (3) with a compound having the formula (2) according to the reaction scheme:



in which (a), W, X and Y are as defined in claim 1.